Based on these observations, investigators have suggested that there may be an interaction-mediated crosstalk existing between the drug efflux pumps and retinoids inhibitors of P-gp1, BCRP and MRP1 that may improve the response to retinoids in cancer [40,41,42]. This evidence concerns the gene CD44 and cancer.